Is taking Lantus (insulin glargine) 100 units at night an appropriate regimen for managing diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Lantus 100 Units at Night for Diabetes Management

Lantus (insulin glargine) 100 units at night is likely excessive as an initial dose for most patients with diabetes and should be carefully titrated based on individual insulin requirements, with typical starting doses being much lower (4 units or 10% of total daily insulin requirements). 1

Appropriate Insulin Glargine Dosing

  • For patients initiating basal insulin therapy, the recommended approach is to start with a lower dose (4 units per day or 10% of total daily insulin requirements) and gradually titrate upward 1
  • Insulin doses should be increased by 1-2 units or 10-15% based on fasting blood glucose measurements 1
  • Total daily insulin requirements typically range from 0.4 to 1.0 units/kg/day for patients with diabetes, with approximately 50% provided as basal insulin 1
  • A dose of 100 units at night would be appropriate only for patients with significant insulin resistance, typically those with type 2 diabetes who weigh approximately 100 kg (220 lbs) or more 1

Benefits of Insulin Glargine (Lantus)

  • Insulin glargine provides relatively constant basal insulin levels over 24 hours with no pronounced peak, making it suitable for once-daily dosing 2
  • Compared to NPH insulin, Lantus is associated with:
    • Lower risk of hypoglycemia, especially nocturnal episodes (26% reduction in nocturnal hypoglycemia) 3
    • Reduced risk of severe hypoglycemia by 46% while achieving similar glycemic control 3
    • More consistent and predictable absorption 4

Proper Administration

  • Insulin glargine can be administered at any time of day, but should be given at the same time each day for consistency 4
  • For patients with type 2 diabetes, Lantus is often used in combination with oral antidiabetic agents or mealtime insulin 1
  • For patients with type 1 diabetes, Lantus should be used in combination with rapid-acting insulin at mealtimes 1

Titration Approach

  • Titrate based on fasting blood glucose levels, with an ideal target of <100 mg/dL to achieve HbA1c <7% 5
  • A systematic titration algorithm for insulin glargine:
    • Increase dose by 0-2 units if mean fasting glucose is 100-120 mg/dL
    • Increase by 2 units if fasting glucose is 120-140 mg/dL
    • Increase by 4 units if fasting glucose is 140-180 mg/dL
    • Increase by 6-8 units if fasting glucose is >180 mg/dL 5
  • Reduce dose by 10-20% if hypoglycemia occurs 1

Special Considerations

  • In obese, insulin-resistant patients, high doses may be required, but it may be better to administer in two separate doses rather than a single large dose 6
  • For patients with variable insulin sensitivity throughout the day, consider switching from evening dosing to morning dosing 1
  • For patients on corticosteroids, morning dosing of basal insulin may be more appropriate 1
  • If a patient is experiencing frequent hypoglycemia on a high dose of Lantus, consider:
    • Splitting the dose into twice-daily administration 6
    • Evaluating for other causes of hypoglycemia 1
    • Considering U-300 glargine or insulin degludec which may have lower hypoglycemia risk 1

Monitoring and Safety

  • Monitor fasting blood glucose regularly to guide dose adjustments 5
  • Be vigilant for signs of hypoglycemia, especially when initiating or increasing insulin doses 3
  • For patients requiring very high insulin doses (>0.5 units/kg/day), consider adding other glucose-lowering agents with complementary mechanisms of action 1

Starting with 100 units of Lantus at night would be excessive for most patients unless they have significant insulin resistance and have been carefully titrated to this dose over time based on blood glucose monitoring.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Insulin glargine (Lantus).

International journal of clinical practice, 2002

Research

[Medication of the month. Insulin glargine (Lantus)].

Revue medicale de Liege, 2004

Research

Insulin Glargine: a review 8 years after its introduction.

Expert opinion on pharmacotherapy, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.